Abstract
[Truncated abstract] Type 2 diabetes mellitus (T2DM) markedly increases the risk of all forms of cardiovascular disease (CVD). Arterial dysfunction is an early feature and predictor of diabetic vascular disease and is causally related to diabetic dyslipidaemia. Statins, recommended as first-line therapy for diabetic dyslipidaemia, decrease CVD events principally by reducing LDL particle concentrations. However, their vascular benefits may be attenuated by inhibition of coenzyme Q10 (CoQ10) production. Therapeutic guidelines recommend LDL-cholesterol be lowered to a target goal of
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Publication status | Unpublished - 2011 |